Navigating the Future: Anti-Asthmatics And COPD Drugs Market Trends and Forecast Insights, 2025 Edition

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Anti-Asthmatics And COPD Drugs Market Size Growth Forecast: What to Expect by 2025?
In recent times, the market size of anti-asthmatics and COPD drugs has seen significant growth. Anticipated to increase from $80.82 billion in 2024 to $86.11 billion in 2025, it will boast a compound annual growth rate (CAGR) of 6.6%. The past growth of this market sector can be linked to causes including a rise in respiratory illnesses, an increase in tobacco smoking, effects of global warming, an ageing population, emerging markets, innovative drug discovery methods, and escalated healthcare spending.

How Will the Anti-Asthmatics And COPD Drugs Market Size Evolve and Grow by 2029?
Projected to experience robust growth in the upcoming years, the market for anti-asthmatics and COPD drugs is estimated to reach a size of $107.01 billion in 2029, expanding at a compound annual growth rate (CAGR) of 5.6%. This anticipated surge during the forecast period is driven by several factors such as the rising use of e-cigarettes/vaping, escalating obesity rates, advancements in technology, a significant percentage of undiagnosed patients, administration of anti-asthmatics and COPD drugs for COVID-19 treatment, and increased intake of fats. Key market trends during this period are expected to include the development of probiotic drugs for asthma, expanding business portfolios with anti-il-5 drugs, launching new groundbreaking products for solidifying market presence and navigating stiff market competition, investing heavily in bioelectric medicine development, focusing on fostering more collaborations, offering personalized treatments, and creating combination drugs for enhanced results, along with the development of biologics to tap into the escalating demand for such products.

View the full report here:
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

What Drivers Are Propelling the Growth of Anti-Asthmatics And COPD Drugs Market Forward?
The anti-asthmatics and COPD drugs market is propelled by modifiable risk factors such as smoking, sedentary lifestyle, and poor diet. Despite a global decline in smoking rates, developing nations like China, India, Indonesia, and Nigeria are observing an opposite trend, with the smoking population rising. For example, Indonesia is expected to see a rise of 24 million smokers and Nigeria, 7 million smokers by 2025, while over 40% of the world's cigarette consumption is centered in China. Furthermore, there is a higher intake of fats, including saturated fatty acids, correlated with an increased risk of Asthma and COPD, especially in affluent nations like the USA and Europe. The World Health Organization points out that in developed countries, fats contribute to over 35% of the total energy needs, which is higher in comparison to less than 20% in low-income countries and under 25% in lower-middle-income countries.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3802&type=smp

Which Emerging Trends Are Transforming the Anti-Asthmatics And COPD Drugs Market in 2025?
Market leaders in the anti-asthmatics and COPD drug industry are spearheading innovations such as the fixed-dose combination (FDC) drug, Indacaterol plus Mometasone, aiming to bolster their market profitability. Used with the Breezhaler device, the Indacaterol plus Mometasone is a once-daily FDC regimen specifically designed to manage asthma symptoms consistently. For example, June 2022 saw the launch of a new FDC drug, Indacaterol plus Mometasone, by Glenmark Pharmaceuticals, a US-based pharma firm, aimed at patients dealing with uncontrollable asthma in India. The drug, marketed under the brand name Indamet, is available in three different doses, each comprising a standard 150 mcg dose of Indacaterol and varying amounts of Mometasone, specifically, 80 mcg, 160 mcg, and 320 mcg.

What Are the Key Segments in the Anti-Asthmatics And COPD Drugs Market?
The anti-asthmatics and COPD drugs market covered in this report is segmented -

1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers
3) By End User: Asthma Patients, COPD Patients
4) By Therapy: Preventive, Curative
5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous
6) By Age Group: Below 5, 5-14, 15-60, Above 60

Subsegments:
1) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics (Short-Acting And Long-Acting), Methylxanthines
2) By Anti-Inflammatory Drugs: Corticosteroids (Inhaled And Systemic), Leukotriene Modifiers, Phosphodiesterase-4 Inhibitors
3) By Monoclonal Antibodies: Anti-IgE Antibodies, Anti-IL-5 Antibodies, Anti-IL-4 Or IL-13 Antibodies
4) By Combination Drugs: Combination Bronchodilator Inhalers (LABA + LAMA), Inhaled Corticosteroid + Long-Acting Beta-Agonist (ICS + LABA)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3802&type=smp

Who Are the Key Players Shaping the Anti-Asthmatics And COPD Drugs Market's Competitive Landscape?
Major companies operating in the anti-asthmatics and COPD drugs market include GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Sumitomo Dainippon Pharma Co. Ltd., China National Pharmaceutical Group Co. Ltd. (Sinopharm), Shanghai Acebright Pharmaceuticals Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd, Hanmi Pharmaceutical, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, Shanghai Anovent Pharma, China Meheco Group Co. Ltd., Lupin Limited, ASGEN Pharmaceutical Co. Ltd, Abbott Laboratories, Pfizer, Vectura Group, Bristol Myers Squibb, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Bayer, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Aspen Nigeria

What Geographic Markets Are Powering Growth in the Anti-Asthmatics And COPD Drugs Market?
North America was the largest region in the anti-asthmatics and COPD drugs market in 2024. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and COPD drugs market during the forecast period. The regions covered in the anti-asthmatics and COPD drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3802

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.